This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Graziani, G. Articles by Navarra, P. Search for Related Content PubMed PubMed Citation Articles by Graziani, G. Articles by Navarra, P.

CRH Inhibits Cell Growth of Human Endometrial Adenocarcinoma Cells via CRH-Receptor 1-Mediated Activation of cAMP-PKA Pathway

Institute of Pharmacology, Catholic University Medical School (G.T., G.P., M.B., P.N.), Rome 00168, Italy; Pharmacology and Medical Oncology Section, Department of Neuroscience, University of Rome "Tor Vergata" (G.G., L.T., I.P.), Rome 00133, Italy

Address all correspondence and requests for reprints to: Prof. Pierluigi Navarra, Institute of Pharmacology, Catholic University Medical School, Largo Francesco Vito 1-00168 Rome, Italy. E-mail: . pnavarra{at}rm.unicatt.it

CRH produced by human endometrial cells exerts decidualizing activity via an autocrine mechanism mediated via CRH-R1 receptors. We postulated that such activity exerted by CRH on normal endometrial cells might translate into an antiproliferative action on endometrial-derived malignancies, provided that neoplastic cells maintain the expression of CRH receptors. In this light, here we investigated the possible antiproliferative effects of CRH in an adenocarcinoma cell line derived from human endometrium.

CRH induces time- and concentration-dependent inhibition of Ishikawa cell growth, the maximal effect (50% inhibition) being achieved after 3 d of treatment with 10^-7 M CRH. A decrease in telomerase activity, which paralleled tumor growth inhibition, was also observed in CRH-treated samples. The antiproliferative effect was confirmed by colony-formation assay for long-term survival. This effect was counteracted in a concentration-dependent manner by both -helical CRH and astressin; the former also showed intrinsic inhibitory activity. These findings suggested the involvement of CRH-R1 receptor subtype; this hypothesis was confirmed by RNase protection analysis showing the expression of human CRH-R1 mRNA. Experiments with the PKA inhibitor 14–22 amide and forskolin, as well as the measurement of intracellular cAMP, suggested the downstream involvement of cAMP-PKA pathway in CRH-induced inhibition of Ishikawa cell growth.

This article has been cited by other articles:

				Z. Hao, Y. Huang, J. Cleman, I. S. Jovin, W. W. Vale, T. L. Bale, and F. J. Giordano Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation PNAS, March 11, 2008; 105(10): 3939 - 3944. [Abstract] [Full Text] [PDF]

				P. Florio, G. De Falco, E. Leucci, M. Torricelli, P. B Torres, P. Toti, A. Dell'Anna, E. Tiso, R. Santopietro, L. Leoncini, et al. Urocortin expression is downregulated in human endometrial carcinoma. J. Endocrinol., July 1, 2006; 190(1): 99 - 105. [Abstract] [Full Text] [PDF]

				E. W. Hillhouse and D. K. Grammatopoulos The Molecular Mechanisms Underlying the Regulation of the Biological Activity of Corticotropin-Releasing Hormone Receptors: Implications for Physiology and Pathophysiology Endocr. Rev., May 1, 2006; 27(3): 260 - 286. [Abstract] [Full Text] [PDF]

				J. Cao, C. L. Cetrulo, and T. C. Theoharides Corticotropin-Releasing Hormone Induces Vascular Endothelial Growth Factor Release from Human Mast Cells via the cAMP/Protein Kinase A/p38 Mitogen-Activated Protein Kinase Pathway Mol. Pharmacol., March 1, 2006; 69(3): 998 - 1006. [Abstract] [Full Text] [PDF]

				N. Papadopoulou, J. Chen, H. S. Randeva, M. A. Levine, E. W. Hillhouse, and D. K. Grammatopoulos Protein Kinase A-Induced Negative Regulation of the Corticotropin-Releasing Hormone R1{alpha} Receptor-Extracellularly Regulated Kinase Signal Transduction Pathway: The Critical Role of Ser301 for Signaling Switch and Selectivity Mol. Endocrinol., March 1, 2004; 18(3): 624 - 639. [Abstract] [Full Text] [PDF]

				J. C. Reubi, B. Waser, W. Vale, and J. Rivier Expression of CRF1 and CRF2 Receptors in Human Cancers J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3312 - 3320. [Abstract] [Full Text] [PDF]

				G. Graziani, L. Tentori, I. Portarena, M. Vergati, and P. Navarra Valproic Acid Increases the Stimulatory Effect of Estrogens on Proliferation of Human Endometrial Adenocarcinoma Cells Endocrinology, July 1, 2003; 144(7): 2822 - 2828. [Abstract] [Full Text] [PDF]